About Kenneth Hoberman
Kenneth Hoberman is a director at TG Therapeutics.
Form D filings name Kenneth Hoberman as an executive officer and director at Lirum Therapeutics.
Kenneth Hoberman reports to the SEC as a director or officer of 3 public companies, including Nuvectis Pharma (NVCT) and Stemline Therapeutics (STML).
Kenneth Hoberman first appears on SEC filings in 2013.
Experience
This experience comes from SEC filings. The years are when the filings name Kenneth Hoberman in the role, so the role may have started earlier or lasted longer.
TI
TG Therapeutics, Inc.
Director
2014 – 2026 · Public company (TGTX)
NI
Nuvectis Pharma, Inc.
Director
2022 – 2026 · Public company (NVCT)
SI
Stemline Therapeutics Inc.
Chief Operating Officer
2013 – 2020 · Public company (STML)
Key Colleagues at Startups
The people Kenneth Hoberman works with at each company, as listed on that company's latest Form D.
Lirum Therapeutics, Inc. · Form D, Feb 23, 2023